Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, MasterCard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Diğerleri
TradFi
WCTC S8
Rewards
PFE

Pfizer Price

Closed
PFE
$27,56
+$0,34(+%1,24)

*Data last updated: 2026-04-19 11:30 (UTC+8)

As of 2026-04-19 11:30, Pfizer (PFE) is priced at $27,56, with a total market cap of $156,77B, a P/E ratio of 18,21, and a dividend yield of %6,24. Today, the stock price fluctuated between $27,13 and $27,67. The current price is %1,58 above the day's low and %0,39 below the day's high, with a trading volume of 29,94M. Over the past 52 weeks, PFE has traded between $21,97 to $28,74, and the current price is -%4,10 away from the 52-week high.

PFE Key Stats

Yesterday's Close$27,22
Market Cap$156,77B
Volume29,94M
P/E Ratio18,21
Dividend Yield (TTM)%6,24
Dividend Amount$0,43
Diluted EPS (TTM)1,36
Net Income (FY)$7,77B
Revenue (FY)$62,57B
Earnings Date2026-05-05
EPS Estimate0,74
Revenue Estimate$13,87B
Shares Outstanding5,75B
Beta (1Y)0.388
Ex-Dividend Date2026-01-23
Dividend Payment Date2026-03-06

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOAlbert Bourla
HeadquartersNew York City,NY,US
Official Websitehttps://www.pfizer.com
Employees (FY)75,00K
Average Revenue (1Y)$834,38K
Net Income per Employee$103,60K

Pfizer (PFE) FAQ

What's the stock price of Pfizer (PFE) today?

x
Pfizer (PFE) is currently trading at $27,56, with a 24h change of +%1,24. The 52-week trading range is $21,97–$28,74.

What are the 52-week high and low prices for Pfizer (PFE)?

x

What is the price-to-earnings (P/E) ratio of Pfizer (PFE)? What does it indicate?

x

What is the market cap of Pfizer (PFE)?

x

What is the most recent quarterly earnings per share (EPS) for Pfizer (PFE)?

x

Should you buy or sell Pfizer (PFE) now?

x

What factors can affect the stock price of Pfizer (PFE)?

x

How to buy Pfizer (PFE) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

PFE
CFD
Trade

Hot Posts About Pfizer (PFE)

GateUser-fcd5a053

GateUser-fcd5a053

04-18 09:30
TermMaxFi @termmaxfi Launches tokenized stock collateralized lending on BNB Chain, supporting 10 tokenized stocks such as AAPL, NVDA, TSLA, and more, with fixed lending periods of 14 days, 45 days, and 75 days. TermMaxFi's fixed-rate lending protocol has been operating stably for over 102 days, with its core design addressing the pain points of high volatility, instability, and inability to ensure returns when needed in DeFi. The TermMaxFi protocol integrates options strategy features, allowing users to buy put options as insurance while borrowing ETH to go long; some users have reduced losses by 15% during market downturns using this strategy. TermMaxFi has launched a points ranking system where users earn points through participating in lending, providing liquidity, or submitting suggestions; the protocol also hosts monthly competitions on themes like highest returns and best strategies to enhance community engagement. Participation methods: Engage in fixed-rate lending on the TermMaxFi protocol, choosing lock-in periods of 14, 45, or 75 days, or use tokenized stocks such as AAPL, NVDA, TSLA, GOOGL, AMZN, MSFT, NFLX, SPY, Q, PFE as collateral for borrowing.
BNB-%1,58
ETH-%1,05
0
0
0
0
Nebraskangoo

Nebraskangoo

04-16 13:05
$PFE As @BigCheds pointed out this is at a key level. High volume reaction at trendline again Good R:R for long term investors.
0
0
0
0
GateUser-bd883c58

GateUser-bd883c58

03-30 08:08
This report (chinatimes.net.cn) reporter Hu Yawen reports from Beijing An increasing number of new energy companies must face the implications of the U.S. “Inflation Reduction Act.” Should they abandon the North American market or rebuild their overseas structure? Rongbai Technology (688005.SH) has chosen the latter. On March 17, Rongbai Technology announced plans to reduce the Chinese ownership ratio of its wholly-owned subsidiary in South Korea to below 25% through a series of operations, including equity transfers, to gain Non-PFE (non-prohibited foreign entity) status, thereby revitalizing the capacity of its South Korean ternary cathodes, which has accumulated an investment of 2.472 billion yuan. As of the time of publication, a reporter from the “Hua Xia Times” had sent inquiries to Rongbai Technology regarding related issues but had not received a response. This transaction involves the establishment of a joint venture by Rongbai Technology and its actual controller, Bai Houshan, the repayment of the South Korean subsidiary's 1.088 billion yuan in existing debt, and the protection of Rongbai Technology's future interests in the North American market. Well-known tax and accounting expert and senior certified public accountant Liu Zhigeng told a reporter from the “Hua Xia Times,” “This transaction is formally a premium sale, but overall it resembles a strategic divestiture of loss-making assets to avoid policy risks. The core goal is to adjust equity to make Singapore AKB the Non-PFE entity, thereby restoring supply qualifications in the North American market.” **Survival and Loss Prevention** In 2013, Laishi Energy Co., Ltd. (hereinafter referred to as “Korean JS”) was established as a wholly-owned subsidiary of Rongbai Technology, representing an investment of 2.472 billion yuan to create an overseas production base for cathode materials. Korean JS has successively built high-nickel ternary cathode production capacities of 27,000 tons and 40,000 tons per year, specifically targeting the North American market. Additionally, there are supporting capacities for ternary precursors and investment layouts aimed at the European market. However, the “Inflation Reduction Act” stipulates that enterprises in which Chinese entities hold more than 25% are classified as “prohibited foreign entities” (PFE). Once identified as such, North American customers will be unable to apply for tax incentives for purchasing PFE products. This directly weakens the competitiveness of Chinese enterprises in the North American market. Rongbai Technology stated, “The ternary capacity established in South Korea cannot effectively supply the Chinese and European markets due to economic reasons and the EU’s localization production requirements, and can only target the North American market. However, the company will lose all North American customers due to its PFE status, ultimately leading to idle capacity, continuous losses for Korean JS, asset impairment, and other damages to the company's interests.” Singapore AKB will replace Korean JS as the new entity to take on actual assets. Bai Houshan and Rongbai Technology established Singapore AKB and Korean AKB (a wholly-owned subsidiary of Singapore AKB) by the end of 2025. The announcement revealed that Rongbai Technology plans to split Korean JS into two entities, Korean JS Old and Korean JS New. Among them, Korean JS Old will hold a ternary cathode capacity of 7,000 tons/year and plans to transfer 31% and 69% equity of Korean JS Old to Singapore AKB and Korean AKB, respectively. The pricing for this transaction has not yet been finalized, but the announcement clearly states that the transaction price will have a certain premium based on the net asset assessment value of Korean JS Old and will not be less than the initial investment cost of fixed assets, with the assessment value expected to exceed $9 million (approximately 620 million yuan). As of the end of 2025, the cumulative investment amount for related assets is $6.8 million, with depreciation of $800,000 already accounted for since its use began in 2024. It is noteworthy that before asset delivery, Korean JS Old needs to repay a total of 1.088 billion yuan in payables to Rongbai Technology. Liu Zhigeng detailed the composition of this debt for reporters: the 1.088 billion yuan in payables consists mainly of two parts, with 91 million yuan being accounts payable arising from daily purchases (such as materials and equipment), and 997 million yuan being funds provided by the parent company for loans, management support, and R&D advances, among other non-trade transactions. Regarding the source of funds for repayment, Liu Zhigeng stated, “The funds for debt repayment do not rely on the operating cash flow of Korean JS Old (which has idle capacity due to PFE restrictions) but come directly from the equity transfer payments made by Singapore AKB and Korean AKB. The transaction funds will fully flow back to the listed company before asset delivery, ensuring a closed loop for debt repayment.” After the relevant transaction involving Korean JS Old is completed, Korean AKB will gradually purchase the remaining ternary cathode capacity owned by Korean JS New based on financing progress. Ultimately, Singapore AKB will take over the current ternary capacity of 67,000 tons/year held by Korean JS as a Non-PFE and will conduct North American business. Rongbai Technology will hold a 24.9% equity stake in Singapore AKB, enabling it to share its operating profit under the equity method in the future. **How to Ensure Voice?** Behind Singapore AKB is the actual controller of Rongbai Technology, Bai Houshan. In the past year, Rongbai Technology and Bai Houshan established a joint venture company, Singapore AKB, in collaboration with Amkobay Holding Pte. Ltd. (hereinafter referred to as “Singapore Company”). Rongbai Technology invested 124,500 Singapore dollars (approximately 680,000 yuan) in Singapore AKB through Korean JS, corresponding to an equity ratio of 24.9%; the Singapore Company invested 375,500 Singapore dollars (approximately 2.01 million yuan), corresponding to an equity ratio of 75.1%. This means that after this transaction, the core North American business will enter a structure controlled by Bai Houshan with 75.1% of Singapore AKB. Subsequently, Singapore AKB will also introduce third-party overseas investors and battery funds, and the proposed battery fund will become the main shareholder of Singapore AKB. For Rongbai Technology, after the transaction is completed, it will only hold a minority stake of 24.9% in Singapore AKB. Under the leadership of the actual controller and with the potential for new investors to be introduced later, how can Rongbai Technology ensure its voice? Liu Zhigeng stated that as a minority shareholder of Singapore AKB, Rongbai Technology's voice does not depend on its shareholding ratio but is realized through contractual rights in the shareholder agreement (SHA). The core protection mechanism of this agreement includes board seats, veto rights on major matters, rights to information and audits, rights of first refusal, and anti-dilution protection, “These terms are standard SPV governance practices internationally, especially in the new energy sector, where Chinese enterprises commonly adopt such structures when establishing Non-PFE entities overseas. Although the announcement did not disclose the specific agreement text, the statement that ‘fully protects the interests of minority shareholders’ implicitly indicates the existence of such contractual arrangements.” From a revenue perspective, after the adjustment of the Korean asset equity, Rongbai Technology's future sources of income will include one-time equity transfer payments and ongoing operational profits derived from the equity method. However, sustainable revenue depends on the profitability of Singapore AKB, and whether Singapore AKB can successfully penetrate the North American market and respond to ongoing changes in U.S. policy remains uncertain. In the past two years, Korean JS has continued to incur losses. In 2024 and 2025, Korean JS's operating revenues are projected to be 684 million yuan and 1.277 billion yuan, respectively; the net profits excluding non-recurring items are projected to be -206 million yuan and -163 million yuan, respectively. Rongbai Technology stated, “Last year, Korean JS's operating revenue accounted for 10.41% of the company's total revenue, with a net profit of -164 million yuan. This adjustment in the Korean business will not have a significant adverse impact on the company. After the adjustment, Singapore AKB and its subsidiaries will be strictly limited to conducting cathode material business in the North American market, while Rongbai Technology will be strictly limited to other non-North American regional markets, ensuring clear business boundaries and independent customer structures for both parties.” From a strategic perspective, this equity adjustment is a proactive measure by Rongbai Technology to address uncertainties; however, this transaction still faces multiple risks. The announcement warns that if policies related to the “Inflation Reduction Act” change, or if other relevant policies in the North American market are adjusted, the effects of the equity adjustment may fall short of expectations. Editor: Li Weilai Chief Editor: Zhang Yuning
0
0
0
0